Skip to main content
. 2023 Aug 2;16(10):1911–1922. doi: 10.1111/cts.13598

TABLE 2.

Safety profile.

AE Keverprazan 20 mg Keverprazan 40 mg Vonoprazan 20 mg Placebo
N 8 8 4 6
Any 3 (37.50%) 6 (75.00%) 2 (50.00%) 3 (50.00%)
TRAE 2 (25.00%) 2 (25.00%) 2 (50.00%) 3 (50.00%)
SAE 0 0 0 0
AE leading to study discontinuation 1 (12.50%) 0 0 0

Abbreviations: AE, adverse event; SAE, severe adverse event; TRAE: treatment‐related adverse event.